Terms: = Lymphoma AND DNMT3A, Q9Y6K1, 1788, ENSG00000119772, DNMT3A2, M_HsaIIIA AND Clinical Outcome
2 results:
1.
Bond J; Touzart A; Leprêtre S; Graux C; Bargetzi M; Lhermitte L; Hypolite G; Leguay T; Hicheri Y; Guillerm G; Bilger K; Lhéritier V; Hunault M; Huguet F; Chalandon Y; Ifrah N; Macintyre E; Dombret H; Asnafi V; Boissel N
Haematologica; 2019 Aug; 104(8):1617-1625. PubMed ID: 30655366
[TBL] [Abstract] [Full Text] [Related]
2. Negative impact on clinical outcome of the mutational co-occurrence of SF3B1 and dnmt3a in refractory anemia with ring sideroblasts (RARS).
Martín I; Such E; Navarro B; Vicente A; López-Pavía M; Ibáñez M; Tormo M; Villamón E; Gómez-Seguí I; Luna I; Oltra S; Pedrola L; Sanz MA; Cervera J; Sanz G
Leuk Lymphoma; 2017 Jul; 58(7):1686-1693. PubMed ID: 27771989
[TBL] [Abstract] [Full Text] [Related]
